Market Place
Sourcing Support
Amplia Opens U.S. Sites for Amplicity Pancreatic Cancer Trial
11 Feb 2026 //
GLOBENEWSWIRE
Amplia Therapeutics Releases Q3 Activities and Cash Flow Report
30 Jan 2026 //
GLOBENEWSWIRE
Narmafotinib Large-Scale Manufacturing Complete
22 Jan 2026 //
GLOBENEWSWIRE
ACCENT DATA Showcased AT 2026 ASCO GI Cancer Symposium
12 Jan 2026 //
GLOBENEWSWIRE
Amplia Therapeutics To Present At 2026 ASCO Gi Cancers Symposium
23 Dec 2025 //
GLOBENEWSWIRE
Amplia Partners Next&Bio For FAK And Kras Inhibitor Combo Therapy
19 Dec 2025 //
GLOBENEWSWIRE
Amplia Investor Presentation Reveal Additional Confirmed Response
12 Dec 2025 //
GLOBENEWSWIRE
Key Narmafotinib Patent Granted In U.S.
03 Dec 2025 //
GLOBENEWSWIRE
FDA Fast Track For Narmafotinib In Advance Pancreatic Cancer
19 Sep 2024 //
PR NEWSWIRE
FDA Clearance Of Amplia`S Ind For Pancreatic Cancer Trial In Us
17 Jan 2024 //
PR NEWSWIRE
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects Pancreatic Cancer
29 May 2023 //
PR NEWSWIRE
Amplia partners with CSIRO to develop wound healing solutions
23 May 2023 //
BIOSPECTRUM ASIA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.